<DOC>
	<DOC>NCT01868997</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and effectiveness of a fully human antibody compared to placebo in the treatment of patients with active thyroid eye disease. "Funding Source - FDA OOPD"</brief_summary>
	<brief_title>Teprotumumab Treatment in Patients With Active Thyroid Eye Disease</brief_title>
	<detailed_description>A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<criteria>Clinical diagnosis of Graves'disease associated with active thyroid eye disease and a clinical activity score of &gt;4 Fewer than 9 months from onset of thyroid eye disease No previous medical or surgical treatment, excluding local supportive measures and steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent with at least 6 weeks between last administration of steroids and randomization Euthyroid or with mild hypo or hyperthyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below the normal limits. Every effort should be made to correct the mild hypo or hyperthyroidism promptly. Optic neuropathy Corneal decompensation unresponsive to medical management Oral or IV steroid treatment for any reason in the preceding 3 months Poorly controlled diabetes Platelets &lt;100 x 109/L Hemoglobin concentration &gt; 2gr/dl below the lower limit of normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated</keyword>
	<keyword>Ophthalmopathy</keyword>
</DOC>